994 Efficacy and Safety of Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Prior Anti-Tumor Therapy: A Subanalysis From the Sharp Trial

Galle, PR; Blanc, Jean‐Frédéric; Laethem, Jean Luc Van; Marrero, Jorge; Beaugrand, Michel; Moscovici, M.; Shan, Ming; Nadel, Andrea; Voliotis, D.; Bruix, Jordi; Llovet, Josep M.

doi:10.1016/s0168-8278(08)60996-4

Cited by 13 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As illustrated in Fig. 4, among similar populations, radioembolization provides a very similar survival as sorafenib [47,[49][50][51][52]. Since both the aim and outcomes of radioembolization can be quite different across tumor stages, we will review the available evidence supporting its potential role in the different stages of HCC using the Barcelona Clinic Liver Cancer (BCLC) classification as the framework since it has been endorsed by the two main Western hepatology societies [19,53].…”

Section: Treatment Outcomes and Potential Roles According To Tumor Stmentioning

confidence: 99%

“…The scientific evidence supporting this recommendation is based on the results from two positive randomized controlled trials [57,58] and two further metanalyses of patients treated with TACE or bland embolization [59,60]. Data for 189 radioembolization-treated patients was obtained from subanalysis of a cohort of patients fulfilling the same inclusion criteria, namely Child-Pugh class A and either BCLC stage C or BCLC stage B with prior TACE or bulky disease (bilobar or >5 nodules) [33,47,[49][50][51][52].…”

Section: Intermediate and Early Stagesmentioning

confidence: 99%

See 1 more Smart Citation

Radioembolization for hepatocellular carcinoma

Sangro¹,

Iñarrairaegui²,

Bilbao³

2012

Journal of Hepatology

261

136

View full text Add to dashboard Cite

Radioembolization is a form of brachytherapy in which intra-arterially injected (90)Y-loaded microspheres serve as sources for internal radiation purposes. It produces average disease control rates above 80% and is usually very well tolerated. Main complications do not result from the microembolic effect, even in patients with portal vein occlusion, but rather from an excessive irradiation of non-target tissues including the liver. All the evidence that support the use of radioembolization in HCC is based on retrospective series or non-controlled prospective studies. However, reliable data can be obtained from the literature, particularly since the recent publication of large series accounting for nearly 700 patients. When compared to the standard of care for the intermediate and advanced stages (transarterial embolization and sorafenib), radioembolization consistently provides similar survival rates. Two indications seem particularly appealing in the boundaries of these stages for first-line radioembolization. First, the treatment of patients straddling between the intermediate and advanced stages (intermediate patients with bulky or bilobar disease that are considered poor candidates for TACE, and advanced patients with solitary tumors invading a segmental or lobar branch of the portal vein). Second, the treatment of patients that are slightly above the criteria for resection, ablation or transplantation, for which downstaging could open the door for a radical approach. Radioembolization can also be used to treat patients progressing to TACE or sorafenib. With a number of clinical trials underway, the available evidence shows that it adds a significant value to the therapeutic weaponry against HCC of tertiary care centers dealing with this major cancer problem.

show abstract

Section: Treatment Outcomes and Potential Roles According To Tumor Stmentioning

confidence: 99%

Section: Intermediate and Early Stagesmentioning

confidence: 99%

Radioembolization for hepatocellular carcinoma

Sangro¹,

Iñarrairaegui²,

Bilbao³

2012

Journal of Hepatology

261

136

View full text Add to dashboard Cite

show abstract

“…2) and is generally well tolerated regardless of patient performance status and presence of MVI and/or EHS [9,16,17]. Ad hoc subanalyses of the SHARP data also suggest that the clinical benefits of sorafenib are maintained irrespective of HCV infection-related [18] or alcohol-related aetiology [19], and prior curative treatment or TACE [20].…”

Section: Sorafenib: First Systemic Therapy To Extend Survival In Hepamentioning

confidence: 99%

“…Subgroup analyses have also shown that the clinical benefits of sorafenib are maintained regardless of patient characteristics including performance status, presence/absence of MVI/EHS, HCC aetiology and prior antitumour therapy [9,[16][17][18][19][20].…”

Section: Sorafenib: First Systemic Therapy To Extend Survival In Hepamentioning

confidence: 99%

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma

Peck‐Radosavljevic¹,

Greten

Lämmer

et al. 2010

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

An expert panel was convened to reach a consensus on the current use of sorafenib in the treatment of hepatocellular carcinoma (HCC). A multinational, multidisciplinary group of experts objectively reviewed clinical data of sorafenib and considered clinical experience to develop statements summarizing our consensus on the current use of sorafenib. Sorafenib is the standard of care for Child-Pugh (CP) A patients with advanced HCC (i.e. not amenable to surgery or locoregional treatment). There is currently insufficient evidence to support the routine clinical use of sorafenib in CP B patients, but sorafenib can be offered as an option for those with compensated liver cirrhosis. Patients with stable performance status who have progressive disease during sorafenib treatment can be maintained on sorafenib, although there are no clear data supporting the continuation of sorafenib in these patients. The effectiveness of the adjuvant use of sorafenib in preventing recurrence after resection or local ablation, or in combination with transarterial chemoembolization, are being evaluated in clinical studies. In conclusion, sorafenib has extended treatment options for patients with HCC, and is now established as the standard of care for CP A patients with HCC not amenable to surgery or locoregional treatment. Based on its multikinase-inhibitor activity and proven efficacy in prolonging survival in HCC, broader use - including a subgroup of patients with CP B (clinically compensated cirrhosis) and earlier disease stages - might be expected dependent on the results of ongoing studies of safety and clinically relevant benefit in these patients.

show abstract

“…According to the above-mentioned guidelines, sorafenib is the treatment of choice in patients with advanced stage (BCLC-C), with reported median survival times in the range of 6.5-10.7 months [39,40,41]. According to the available data, patients with advanced disease treated with radioembolization achieved a median survival ranging from 6 to 10 months [6,7] and therefore comparable to the results reported with sorafenib [42].…”

Section: What Is the Role Of Radioembolization In Hcc Treatment? Currmentioning

confidence: 99%

Trans-Arterial Radioembolization for Hepatocellular Carcinoma

Sacco

Giorgi²,

Fornaro

et al. 2015

Dig Dis

View full text Add to dashboard Cite

This article offers an overview of a new therapeutic option in hepatocellular carcinoma using trans-arterial radioembolization. In particular, it covers practical aspects of the technique and the currently available preliminary data in terms of disease control. We explore the potentials of radioembolization both in early and advanced stages of the disease, as single treatment and as companion to targeted agents such as sorafenib.

show abstract

994 Efficacy and Safety of Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Prior Anti-Tumor Therapy: A Subanalysis From the Sharp Trial

Cited by 13 publications

References 0 publications

Radioembolization for hepatocellular carcinoma

Radioembolization for hepatocellular carcinoma

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma

Trans-Arterial Radioembolization for Hepatocellular Carcinoma

Contact Info

Product

Resources

About